In these analyses, the expression levels of CD8, CD38, and CD19 in chemo-exposed HL patients were similar to levels in the good outcome group of CN patients, although the down-regulation of CD8 and CD19 expression was significantly lower (−125-fold for CD8 and −19085-fold for CD19) than that in normal samples. The gene discussed is CD19; the disease is Hodgkins lymphoma.